Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Blood (2023) 142 (Supplement 1): 2121.

https://doi.org/10.1182/blood-2023-178629

Published: 2023

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Blood (2023) 142 (Supplement 1): 1029.

https://doi.org/10.1182/blood-2023-177693

Published: 2023

Journal Articles

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Blood (2023) 142 (Supplement 1): 103.

https://doi.org/10.1182/blood-2023-175034

Published: 2023

Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Blood (2022) 140 (Supplement 1): 1852–1855.

https://doi.org/10.1182/blood-2022-162421

Published: 2022

Journal Articles

Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study

Matthew J. Wieduwilt, MD PhD, Leland Metheny, III, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Noel Estrada-Merly, MS, Marcos de Lima, MD, Mark Litzow, MD, Partow Kebriaei, MD, Chris S. Hourigan, MDPhD, Daniel J. Weisdorf, MD, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-137186

Published: 2020

Journal Articles

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Ruta Brazauskas, Graziana M. Scigliuolo, Hai-Lin Wang, Barbara Cappelli, Annalisa Ruggeri, Courtney D. Fitzhugh, Jane S. Hankins, Julie Kanter, Joerg J. Meerpohl, Julie A. Panepinto, Damiano Rondelli, Shalini Shenoy, Mark C. Walters, John E. Wagner, John F. Tisdale, Eliane Gluckman, Mary Eapen

Blood (2020) 136 (5): 623–626.

https://doi.org/10.1182/blood.2020005687

Published: 2020

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Leland Metheny, III, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Natalie Scott Callander, MD, Mark Litzow, MD, Partow Kebriaei, MD, Aric C. Hall, MD, Brenda M Sandmaier, MD, Mei-Jie Zhang, Hai-Lin Wang, MPH, Khalid Bo-Subait

Blood (2019) 134 (Supplement_1): 2036.

https://doi.org/10.1182/blood-2019-125946

Published: 2019

Journal Articles

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Mary-Elizabeth M. Percival, MD, Hai-Lin Wang, MPH, Mei-Jie Zhang, PhD, Elihu H. Estey, MD, Mark Litzow, MD, Partow Kebriaei, MD, Marcos de Lima, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 4585.

https://doi.org/10.1182/blood-2019-123510

Published: 2019

Journal Articles

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Nelli Bejanyan, MD, Mei-Jie Zhang, PhD, Khalid Bo-Subait, Hai-Lin Wang, MPH, Erica D. Warlick, MD, Claudio G Brunstein, MD PhD, Brenda M Sandmaier, MD, Mark Litzow, MD, Partow Kebriaei, MD, Wael Saber, MD MS, Daniel J. Weisdorf, MD

Blood (2019) 134 (Supplement_1): 4603.

https://doi.org/10.1182/blood-2019-123513

Published: 2019

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Blood (2018) 132 (Supplement 1): 2170.

https://doi.org/10.1182/blood-2018-99-118383

Published: 2018

Journal Articles

Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

Rajneesh Nath, MD, Zheng Zhou, MD PhD, Jan Cerny, MD PhD, Hai-Lin Wang, MPH, Khalid Bo-Subait, Zartash Guth, Gulrayz Ahmed, Muhammad Wagas Khan, Gerhard Carl Hildebrandt, MD, Hassan B. Alkhateeb, MD, Moussab Damlaj, MD, Mrinal M. Patnaik, MD MBBS, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Mark R. Litzow, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 3456.

https://doi.org/10.1182/blood-2018-99-116795

Published: 2018

Journal Articles

Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis

Moshe Yeshurun, Daniel J. Weisdorf, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Mary E. Flowers, MD, Marcos De Lima, MD, Jacob M. Rowe, MD, Brenda M. Sandmaier, MD, Martin S. Tallman, MD, Michael R Verneris, MD, Veronika Bachanova, MD PhD

Blood (2017) 130 (Supplement 1): 518.

https://doi.org/10.1182/blood.V130.Suppl_1.518.518

Published: 2017

Journal Articles

Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis

Aleksandr Lazaryan, MD PhD MPH, Michelle Dolan, MD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Veronika Bachanova, MD PhD, Marcos De Lima, MD, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD

Blood (2017) 130 (Supplement 1): 1439.

https://doi.org/10.1182/blood.V130.Suppl_1.1439.1439

Published: 2017

Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 679.

https://doi.org/10.1182/blood.V128.22.679.679

Published: 2016

Journal Articles

Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study

Nelli Bejanyan, MD, Aleksandr Lazaryan, MD PhD MPH, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Marcos de Lima, MD, Brenda M. Sandmaier, MD, Mary M. Horowitz, MD MS, H. Jean Khoury, MD, Daniel J. Weisdorf, MD

Blood (2016) 128 (22): 684.

https://doi.org/10.1182/blood.V128.22.684.684

Published: 2016

Journal Articles

Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis

Fotios V. Michelis, MDPhD, Vikas Gupta, MD FRCP, FRCPath, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Marcos de Lima, MD, Hanna Jean Khoury, MD, Brenda M Sandmaier, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2009.

https://doi.org/10.1182/blood.V126.23.2009.2009

Published: 2015

Journal Articles

Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia

Eric Segal, BS, Michael Martens, MS, Hai-Lin Wang, MPH, Ruta Brazauskas, PhD, Daniel Weisdorf, MD, Brenda M. Sandmaier, MD, Marcos J de Lima, MD, H. Jean Khoury, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 2017.

https://doi.org/10.1182/blood.V126.23.2017.2017

Published: 2015

Journal Articles

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Matthew D. Seftel, MDMPH FRCPC, Donna Neuberg, ScD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Julie Bergeron, MD FRCPC, Stephen Couban, MD FRCPC, Daniel J. DeAngelo, MD PhD, Marcos J de Lima, MD, Steven M. Devine, MD, Mary Eapen, MBBS, Mary M. Horowitz, MD MS, Marcelo C. Pasquini, MD MS, J. Douglas Rizzo, MD, Wael Saber, MD MS, Stephen E. Sallan, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 319.

https://doi.org/10.1182/blood.V124.21.319.319

Published: 2014

Journal Articles

Clinical Relevance of HLA Supertype Matching after Myeloablative Conditioning 7/8 Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Study

Aleksandr Lazaryan, MD PhD MPH, Tao Wang, PhD, Stephen R. Spellman, MBS, Hai-Lin Wang, MPH, Carlheinz R. Müller, MD PhD, Marcelo A. Fernandez-Viña, PhD D(ABHI), Michael R. Verneris, MD, Mukta Arora, MD MS, Daniel J. Weisdorf, MD, Mary M. Horowitz, MD MS, Stephanie J. Lee, MD MPH

Blood (2014) 124 (21): 2572.

https://doi.org/10.1182/blood.V124.21.2572.2572

Published: 2014

NARROW

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Comparative Effectiveness of Axicabtagene Ciloleucel Vs Historical Standard-of-Care in Patients with Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry

Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study

Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia

Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopoietic Cell Transplantation (AlloHCT)

Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index

Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study

Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

Graft-Vs-Leukemia Effect in Acute Lymphoblastic Leukemia: Mild Acute Graft-Vs-Host Disease Protects Against Relapse and Improves Survival after Allogeneic Transplantation: A CIBMTR Analysis

Prognostic Significance of Cytogenetic Abnormalities in Patients with Philadelphia-Negative ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: A CIBMTR Analysis

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Consolidation Chemotherapy Is Not Beneficial for Adult Acute Lymphoblastic Leukemia Patients with Available Donor Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation in First Complete Remission: A CIBMTR Study

Outcomes of Allogeneic Transplantation in Patients Aged ≤ 60 Years with Acute Myeloid Leukemia in Second Complete Remission: A CIBMTR ® Cohort Analysis

Comparison of Post-Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes after Matched Related Donor Versus Matched Unrelated Donor HCT in Adults with Acute Lymphoblastic Leukemia

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Clinical Relevance of HLA Supertype Matching after Myeloablative Conditioning 7/8 Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only